Corvex Management LP bought $3.0M of GeneDx (WGS)
Executed May 14 2025, disclosed May 16 2025, 2 days later.
Over the 21 trading sessions from the disclosed entry session (May 16 2025), the stock returned +3.1% (delay-adjusted); from the execution session (May 14 2025), +8.9%. Derived: entry at the session's open, exit at the close 20 sessions later.
Corvex Management LP (Director) filed 1 Form 4 report as a reporting entity in the past 24 months (1 purchase, 0 sales), most often in GeneDx Holdings Corp. (WGS). Across 1 priced purchase filing, the average 21-session return was +8.9% from execution and +3.1% from disclosure (delay-adjusted; derived). The largest single filing was $3.0M of WGS (50,000 sh across 2 lots, as filed), executed May 14 2025.
Healthcare · GeneDx Holdings Corp., a genomics company, provides genetic testing services
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→